Prime Medicine, Inc.
PRME
$3.67
$0.020.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -61.61% | 486.12% | -- | 146.02% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.61% | 486.12% | -- | 146.02% | -- |
| Cost of Revenue | 1.77% | 9.05% | -23.76% | 4.81% | -17.74% |
| Gross Profit | -6.11% | -6.56% | 50.18% | 34.30% | 23.01% |
| SG&A Expenses | 19.80% | -20.52% | 4.09% | 19.05% | -5.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.55% | 1.39% | -2.12% | 10.04% | -14.92% |
| Operating Income | -9.92% | 0.48% | 4.12% | -8.38% | 18.92% |
| Income Before Tax | -9.00% | 3.69% | 5.17% | -13.73% | 35.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.00% | 3.69% | 4.95% | -13.39% | 35.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.00% | 3.69% | 4.95% | -13.39% | 35.60% |
| EBIT | -9.92% | 0.48% | 4.12% | -8.38% | 18.92% |
| EBITDA | -9.94% | 1.10% | 4.84% | -7.80% | 20.25% |
| EPS Basic | 19.51% | 28.14% | 12.30% | 9.47% | 54.51% |
| Normalized Basic EPS | 17.78% | 26.52% | 11.75% | 14.22% | 44.11% |
| EPS Diluted | 19.51% | 28.14% | 12.30% | 9.47% | 54.51% |
| Normalized Diluted EPS | 17.78% | 26.52% | 11.75% | 14.22% | 44.11% |
| Average Basic Shares Outstanding | 35.42% | 34.02% | 8.39% | 25.29% | 41.59% |
| Average Diluted Shares Outstanding | 35.42% | 34.02% | 8.39% | 25.29% | 41.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |